Cargando…

Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?

British Journal of Cancer (2002) 86, 1664–1664. DOI: 10.1038/sj/bjc/6600314 www.bjcancer.com © 2002 Cancer Research UK

Detalles Bibliográficos
Autores principales: de Wit, R, Stoter, G, Sparreboom, A, Verweij, J, de Boer, A C, vd Linden, G H M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746592/
http://dx.doi.org/10.1038/sj.bjc.6600314
_version_ 1782172053445541888
author de Wit, R
Stoter, G
Sparreboom, A
Verweij, J
de Boer, A C
vd Linden, G H M
author_facet de Wit, R
Stoter, G
Sparreboom, A
Verweij, J
de Boer, A C
vd Linden, G H M
author_sort de Wit, R
collection PubMed
description British Journal of Cancer (2002) 86, 1664–1664. DOI: 10.1038/sj/bjc/6600314 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2746592
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27465922009-09-18 Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade? de Wit, R Stoter, G Sparreboom, A Verweij, J de Boer, A C vd Linden, G H M Br J Cancer Letter to the Editor British Journal of Cancer (2002) 86, 1664–1664. DOI: 10.1038/sj/bjc/6600314 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-05-20 2002-05-03 /pmc/articles/PMC2746592/ http://dx.doi.org/10.1038/sj.bjc.6600314 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editor
de Wit, R
Stoter, G
Sparreboom, A
Verweij, J
de Boer, A C
vd Linden, G H M
Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?
title Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?
title_full Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?
title_fullStr Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?
title_full_unstemmed Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?
title_short Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?
title_sort reply: granisetron vs ondansetron: is it a question of duration of 5-ht(3) receptor blockade?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746592/
http://dx.doi.org/10.1038/sj.bjc.6600314
work_keys_str_mv AT dewitr replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade
AT stoterg replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade
AT sparrebooma replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade
AT verweijj replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade
AT deboerac replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade
AT vdlindenghm replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade